Company news
OSR Holdings, Inc. news in 2026
OSR Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
August 21, 2026
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
August 19, 2026
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
August 19, 2026
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
August 7, 2026
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
August 3, 2026
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
July 31, 2026
OSR Health, A Message From the CEO
July 13, 2026
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
June 25, 2026
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do
June 22, 2026
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
May 27, 2026
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
April 30, 2026
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
April 29, 2026
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
April 8, 2026
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
March 30, 2026
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
March 22, 2026
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
March 19, 2026
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
March 19, 2026
OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum
March 4, 2026
CEO Statement to Shareholders
February 2, 2026
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
January 27, 2026
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch
January 22, 2026
Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
January 16, 2026